Search

Matthew David Onsum

from Woodinville, WA
Age ~47
Get Report
Also known as:
Matthew D Onsum, Matt Onsum
Phone and address:
17816 159Th Ave NE, Woodinville, WA 98072
(617) 676-7088
Related to:
Carol Onsum Pierce, 69Hannah E Koerner, 31
Connected to:
Lisa K Onsum, 41Amber Onsurez, 34Anthony R Onsurez, 41Joseph J Onsurez, 38Raquel D Onsurez, 36Robert A Onsurez, 45Bhuwan R Onta, 47Gordon C Ontai, 90Fernando V Ontaneda, 73Roxana I Ontaneda, 49

Matthew Onsum Phones & Addresses

  • 17816 159Th Ave NE, Woodinville, WA 98072 (617) 676-7088
  • El Cerrito, CA
  • Boston, MA
  • San Francisco, CA
  • Waltham, MA
  • Berkeley, CA
  • Liberty Farms, CA

Business Records

Name / Title
Company / Classification
Phones & Addresses
Matthew Onsum
President
SILVER CREEK PHARMACEUTICALS, INC
Commercial Physical Research
409 Illinois St, San Francisco, CA 94158
1200 Seaport Blvd, Redwood City, CA 94063

Publications

Us Patents

Methods, Systems And Products For Predicting Response Of Tumor Cells To A Therapeutic Agent And Treating A Patient According To The Predicted Response

View page
US Patent:
20110027291, Feb 3, 2011
Filed:
Feb 17, 2010
Appl. No.:
12/707521
Inventors:
Birgit SCHOEBERL - Cambridge MA, US
Brian HARMS - Roslindale MA, US
Francis David GIBBONS - Lexington MA, US
Jonathan Basil FITZGERALD - Cambridge MA, US
Matthew David ONSUM - Jamaica Plain MA, US
Ulrik NIELSEN - Quincy MA, US
William KUBASEK - Belmont MA, US
Assignee:
MERRIMACK PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 39/395
G01N 33/566
A61P 35/00
G06F 7/60
G06F 19/00
US Classification:
4241581, 435 721, 435 723, 703 2, 702 19
Abstract:
The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.

Methods And Systems For Predicting Response Of Cells To A Therapeutic Agent

View page
US Patent:
20110159513, Jun 30, 2011
Filed:
Aug 17, 2009
Appl. No.:
13/058687
Inventors:
Birgit Schoeberl - Cambridge MA, US
Brian Harms - Roslindale MA, US
Francis David Gibbons - Lexington MA, US
Jonathan Basil Fitzgerald - Arlington MA, US
Matthew David Onsum - Jamaica Plain MA, US
Ulrik Nielsen - Quincy MA, US
William Kubasek - Belmont MA, US
Assignee:
MERRIMACK PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
C12Q 1/68
G01N 33/574
US Classification:
435 617, 435 723
Abstract:
The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.

Bi-Specific Fusion Proteins

View page
US Patent:
20110286976, Nov 24, 2011
Filed:
May 20, 2011
Appl. No.:
13/112907
Inventors:
ULRIK NIELSEN - QUINCY MA, US
THOMAS WICKHAM - GROTON MA, US
BIRGIT SCHOEBERL - CAMBRIDGE MA, US
BRIAN HARMS - ROSLINDALE MA, US
BRYAN LINGGI - RICHLAND WA, US
MATTHEW ONSUM - JAMAICA PLAIN MA, US
BYRON DELABARRE - CAMBRIDGE MA, US
Assignee:
MERRIMACK PHARMACEUTICALS - CAMBRIDGE MA
International Classification:
A61K 38/16
C07H 21/04
A61K 35/12
C07K 19/00
A61P 9/00
US Classification:
424 937, 530350, 530399, 5303917, 530380, 530363, 514 164, 514 165, 536 234
Abstract:
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Bi-Specific Fusion Proteins

View page
US Patent:
20110293579, Dec 1, 2011
Filed:
May 20, 2011
Appl. No.:
13/068808
Inventors:
Ulrik Nielsen - Quincy MA, US
Thomas Wickham - Groton MA, US
Birgit Schoeberl - Cambridge MA, US
Brian Harms - Roslindale MA, US
Bryan Linggi - Richland WA, US
Matthew Onsum - Jamaica Plain MA, US
Byron DeLaBarre - Cambridge MA, US
Shaun Lippow - San Francisco CA, US
Assignee:
Merrimack Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 35/12
A61P 43/00
A61K 38/02
C07H 21/00
C07K 19/00
US Classification:
424 937, 536 234, 530350, 530399, 530397, 530351, 5303873, 514 11
Abstract:
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-Specific Fusion Proteins

View page
US Patent:
20210214463, Jul 15, 2021
Filed:
Mar 25, 2021
Appl. No.:
17/212270
Inventors:
- San Francisco CA, US
Thomas Wickham - Groton MA, US
Birgit Schoeberl - Cambridge MA, US
Brian Harms - Roslindale MA, US
Bryan Linggi - Richland WA, US
Matthew Onsum - El Cerrito CA, US
Byron DeLaBarre - Cambridge MA, US
Shaun M. Lippow - San Francisco CA, US
International Classification:
C07K 16/44
B82Y 5/00
C07K 14/475
C12N 15/62
A61K 47/66
A61K 47/68
A61K 45/06
C07K 16/46
C07K 14/47
C07K 14/485
C07K 14/65
Abstract:
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-Specific Fusion Proteins

View page
US Patent:
20210040233, Feb 11, 2021
Filed:
Oct 23, 2020
Appl. No.:
17/078978
Inventors:
- San Francisco CA, US
Thomas Wickham - Groton MA, US
Birgit Schoeberl - Cambridge MA, US
Brian Harms - Roslindale MA, US
Bryan Linggi - Richland WA, US
Matthew Onsum - Jamaica Plain MA, US
Byron DeLaBarre - Cambridge MA, US
International Classification:
C07K 16/44
B82Y 5/00
C07K 14/475
C12N 15/62
A61K 47/66
A61K 47/68
A61K 45/06
C07K 16/46
C07K 14/47
C07K 14/485
C07K 14/65
Abstract:
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Bi-Specific Therapeutic Proteins For Tissue Repair

View page
US Patent:
20200207826, Jul 2, 2020
Filed:
Mar 17, 2020
Appl. No.:
16/820960
Inventors:
- San Francisco CA, US
Shawdee Eshghi - Oakland CA, US
Kristopher M. Kuchenbecker - Los Angeles CA, US
Bjorn L. Millard - Orinda CA, US
Matthew D. Onsum - El Cerrito CA, US
Andrea D. Nickerson - San Francisco CA, US
Timothy R. Stowe - San Francisco CA, US
Yan Zhang - San Francisco CA, US
International Classification:
C07K 14/65
C07K 14/765
C07K 14/47
Abstract:
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

Bi-Specific Fusion Proteins

View page
US Patent:
20200048368, Feb 13, 2020
Filed:
Jul 29, 2019
Appl. No.:
16/524451
Inventors:
- San Francisco CA, US
Thomas Wickham - Groton MA, US
Birgit Schoeberl - Cambridge MA, US
Brian Harms - Roslindale MA, US
Bryan Linggi - Richland WA, US
Matthew Onsum - El Cerrito CA, US
Byron DeLaBarre - Cambridge MA, US
Shaun M. Lippow - San Francisco CA, US
International Classification:
C07K 16/44
C07K 14/65
C07K 14/485
C07K 14/47
C07K 16/46
A61K 45/06
A61K 47/68
A61K 47/66
C12N 15/62
C07K 14/475
B82Y 5/00
Abstract:
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
Control profile
Matthew David Onsum from Woodinville, WA, age ~47 Get Report